EG-HPCP-03a / Evergreen Therap - LARVOL DELTA

Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Evergreen Therapeutics, Inc. | N=96 ➔ 0 | Trial completion date: Aug 2023 ➔ May 2023 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Aug 2023 ➔ May 2023

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Pneumonia

Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia (clinicaltrials.gov) - P2 | N=96 | Not yet recruiting | Sponsor: Evergreen Therapeutics, Inc. | Trial completion date: Dec 2022 ➔ Aug 2023 | Trial primary completion date: Oct 2022 ➔ Aug 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia

Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia (clinicaltrials.gov) - P2; N=96; Not yet recruiting; Sponsor: Evergreen Therapeutics, Inc.; Trial completion date: Dec 2021 ➔ Dec 2022; Initiation date: Jun 2021 ➔ Oct 2021; Trial primary completion date: Oct 2021 ➔ Oct 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Evergreen Therapeutics, Inc. Announces Agreement with ICON plc to Conduct Phase II Clinical Trial for COVID-19 Drug Candidate (GlobeNewswire) - "Evergreen Therapeutics, Inc....announced a clinical service agreement with ICON plc ('ICON') to conduct a global, multi-center Phase II clinical trial for Evergreen’s COVID-19 drug therapy candidate EG-009A....The first patients with COVID-19 are expected to be enrolled in early August 2021, and the Phase II clinical trial is expected to be completed by the middle of 2022. This clinical trial will be conducted in the United States, Brazil, and Argentina, and will be a randomized, double-blinded, and controlled study."

Licensing / partnership • Trial completion date • Trial initiation date • Infectious Disease • Novel Coronavirus Disease

Study to Evaluate the Efficacy and Safety of EG-HPCP-03a Compared to DEX in Patients With COVID-19 Pneumonia (clinicaltrials.gov) - P2; N=96; Not yet recruiting; Sponsor: Evergreen Therapeutics, Inc.; Initiation date: Dec 2020 ➔ Jun 2021

Clinical • Trial initiation date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Study to Evaluate the Efficacy and Safety of EG-HPCP-03a Compared to DEX in Patients With COVID-19 Pneumonia (clinicaltrials.gov) - P2; N=96; Not yet recruiting; Sponsor: Evergreen Therapeutics, Inc.

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases